KR101879506B1 - Extracting method of beta-glucan from Phellinus baumii - Google Patents
Extracting method of beta-glucan from Phellinus baumii Download PDFInfo
- Publication number
- KR101879506B1 KR101879506B1 KR1020160128209A KR20160128209A KR101879506B1 KR 101879506 B1 KR101879506 B1 KR 101879506B1 KR 1020160128209 A KR1020160128209 A KR 1020160128209A KR 20160128209 A KR20160128209 A KR 20160128209A KR 101879506 B1 KR101879506 B1 KR 101879506B1
- Authority
- KR
- South Korea
- Prior art keywords
- glucan
- beta
- present
- ethanol
- extraction
- Prior art date
Links
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title claims abstract description 35
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 22
- 241001556385 Sanghuangporus baumii Species 0.000 title description 4
- 238000000605 extraction Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 21
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000003809 water extraction Methods 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 229920000297 Rayon Polymers 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 10
- 241000121220 Tricholoma matsutake Species 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 15
- 238000000746 purification Methods 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5034—Beta-Glucan
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 상황버섯으로부터 베타글루칸을 높은 순도 및 함량으로 추출 및 정제하는 방법에 관한 것이다. 본 발명의 추출방법에 의해 추출된 베타글루칸 추출물은 기존의 추출법에 의해 추출된 것보다 높은 순도와 함량을 나타내며, 우수한 항암 활성을 가지므로, 항암 활성을 나타내는 약학적 조성물 또는 기능성 식품 조성물로 활용될 수 있다.The present invention relates to a method for extracting and purifying beta-glucan from pine mushroom with high purity and content. Since the beta-glucan extract extracted by the extraction method of the present invention exhibits higher purity and content than those extracted by the conventional extraction method and has excellent anticancer activity, it can be used as a pharmaceutical composition or a functional food composition exhibiting anticancer activity .
Description
본 발명은 상황버섯으로부터 베타글루칸을 높은 순도 및 함량으로 추출하는 방법에 관한 것이다.The present invention relates to a method for extracting beta-glucan from pine mushroom with high purity and content.
버섯의 다당류에는 glucan, schizophyllan, lentinan, galactomannan 및 krestin 등이 있으며, 그 중 베타글루칸(β-glucan)이 많은 수로 존재한다. 베타글루칸은 염증반응을 억제하고, 비특이적 면역 반응으로 면역세포의 기능을 활성화시켜 암세포의 증식과 재발을 억제하는 것으로 알려져 있다. Polysaccharides of mushrooms include glucan, schizophyllan, lentinan, galactomannan, and krestin, among which beta-glucan is present in large numbers. It is known that beta-glucan inhibits the inflammatory reaction and activates immune cell function by nonspecific immune response to inhibit proliferation and recurrence of cancer cells.
상황버섯(Phellinus baumii)은 소나무 비늘버섯과 진흙버섯속에 속하며 주로 뽕나무와 활엽수의 줄기에 자생하는 것으로 알려져 있다. 갓의 표면을 제외한 모두에서 황색을 띠어 상황이라 불리며 전 세계적으로 존재하는 약 220여종 중 국내에서는 Phellinus baumii와 P. linteus가 일반적으로 재배 및 유통되고 있다. Phellinus baumii ) belongs to the genus of pine scales and mud mushrooms and is known to grow mainly in the stem of mulberry and broad - leaved trees. It is said that all except for the surface of the gut, it is yellow, and among the about 220 species in the world, Phellinus baumii and P. linteus are generally cultivated and distributed.
상황버섯의 자실체는 무수한 세포층으로 두껍게 경질화되어 있으며, 그 중의 베타글루칸은 단백결합상태로 세포벽에 존재하며 다량의 비수용성 단백질로 둘러싸여 있다. Fruiting bodies of mushroom are thickened to innumerable cell layers. Betaglucan is in protein bound state and is surrounded by a large amount of non - soluble protein.
종래에는 버섯류의 균사체 또는 자실체로부터 베타글루칸과 같은 유용성분을 추출하는데 있어 열수 추출이나 알코올 등을 이용한 추출이 시도되었다. 그러나 이는 추출 효율이 낮아 유용성분을 효과적으로 분리해낼 수 있는 적절한 전처리 기술이 요구된다. 이에 초고압(한국특허출원 102014-0063083호)이나 초음파(한국특허출원 10-2003-0028783호) 처리 등의 다양한 전처리 및 추출 방법이 연구된 바 있으나 효소를 이용한 가수분해에 의한 연구는 부족한 실정이다.Conventionally, in extracting useful components such as beta-glucan from mushroom mycelium or fruiting body, extraction with hot water or extraction with alcohol has been attempted. However, this requires a proper pretreatment technique to effectively separate useful components because of low extraction efficiency. Various preprocessing and extraction methods such as ultrahigh pressure (Korean Patent Application No. 102014-0063083) and ultrasound (Korean Patent Application No. 10-2003-0028783) have been studied, but studies by hydrolysis using enzymes have been lacking.
본 발명의 목적은 상황버섯으로부터 순도 및 함량이 높은 베타글루칸을 추출하는 방법을 제공하는 것이다.It is an object of the present invention to provide a method for extracting beta-glucan having high purity and high content from a mushroom.
상기 목적을 달성하기 위하여, 본 발명은 상황버섯 분말과 물을 혼합하는 단계; 상기 혼합물에 비스코자임(viscozyme)을 처리하는 효소 전처리 단계; 상기 효소 전처리 단계를 거친 결과물의 pH를 6-7로 조정한 후 열수 추출하는 단계; 및 상기 열수 추출물을 에탄올로 정제하는 단계를 포함하는, 상황버섯으로부터 베타글루칸을 추출하는 방법을 제공한다.In order to accomplish the above object, the present invention provides a method for producing a mushroom powder, An enzyme pretreatment step of treating the mixture with a viscozyme; Adjusting the pH of the resulting product to 6-7, and then subjecting it to hot water extraction; And purifying the hydrothermal extract with ethanol. The present invention also provides a method for extracting beta-glucan from a mushroom.
본 발명의 일실시예에 있어서, 상기 방법은, 상황버섯 분말과 pH 3.5-5.5의 물을 10-30 중량%의 용매비로 혼합하는 단계; 상기 혼합물에 비스코자임(viscozyme)을 처리하는 효소 전처리 단계; 상기 효소 전처리 단계를 거친 결과물의 pH를 6-7로 조정하는 단계; 상기 pH를 6-7로 조정한 결과물을 열수 추출하는 단계; 및 상기 열수 추출물을 에탄올로 2-4회 정제하는 단계를 포함한다.In one embodiment of the present invention, the method comprises mixing a mushroom powder with water at a pH of 3.5-5.5 at a solvent ratio of 10-30% by weight; An enzyme pretreatment step of treating the mixture with a viscozyme; Adjusting the pH of the resulting product through the enzyme pretreatment step to 6-7; Adjusting the pH to 6-7, and subjecting the resultant to hot water extraction; And purifying the hot-water extract with ethanol 2-4 times.
본 발명의 일실시예에 있어서, 상기 효소 전처리 단계의 용매는 pH 4의 물이며, 상황버섯 분말 중량의 10-30배의 중량으로 혼합된다.In one embodiment of the present invention, the solvent of the enzyme pretreatment step is water having a pH of 4 and is mixed at a weight of 10 to 30 times the weight of the mushroom powder.
본 발명의 일실시예에 있어서, 상기 효소 전처리 단계는 0.6-0.7% (v/v)의 비스코자임을 가한 후 40-60℃의 온도에서 6-8시간 동안 교반하는 것을 특징으로 한다. In one embodiment of the present invention, the enzyme pretreatment step is performed by adding 0.6 to 0.7% (v / v) of viscose and stirring at a temperature of 40 to 60 ° C for 6-8 hours.
본 발명의 일실시예에 있어서, 상기 전처리 단계는 25 mesh 이상으로 분쇄한 상황버섯 분말에 pH 3.5-5.5인 약 10-30배의 물을 혼합하고 0.6-0.7% (v/v)의 Viscozyme을 가하여 40-60℃의 온도에서 6-8시간 교반하는 전처리를 진행한다. In one embodiment of the present invention, the pretreatment step comprises mixing about 10-30 times of water having a pH of 3.5-5.5 with a mushroom powder pulverized to a size of 25 mesh or more, adding 0.6-0.7% (v / v) of Viscozyme And the mixture is stirred at a temperature of 40-60 ° C for 6-8 hours.
본 발명의 일실시예에 있어서, 상기 용매의 pH는 0.01 M citric acid로 조정한다. 이에 의하여 세포벽을 분해해 세포 내 구성물질의 방출을 용이하게 할 수 있다. 상기 전처리 단계의 교반은 기계적 방법에 의한 교반을 의미하며, 전처리 시간은 6-8시간으로 할 수 있다.In one embodiment of the present invention, the pH of the solvent is adjusted to 0.01 M citric acid. Thus, it is possible to decompose the cell wall to facilitate the release of constituent substances in the cell. Stirring in the pretreatment step means stirring by mechanical method, and the pretreatment time may be 6-8 hours.
본 발명의 일실시예에 있어서, 상기 효소 전처리 단계를 거친 결과물의 pH를 6-7로 조정하는 단계는 0.01 N NaOH를 이용하는 것을 특징으로 한다.In one embodiment of the present invention, the step of adjusting the pH of the product after the enzyme pretreatment step to 6-7 is characterized by using 0.01 N NaOH.
본 발명의 일실시예에 있어서, 상기 열수 추출 단계는 80-90℃의 온도에서 24시간 동안 열수 추출하는 것을 특징으로 한다. 열수 추출 시간은 24시간까지는 수율 및 베타글루칸 함량이 시간 증가율에 비례하여 증가하였으나, 이 범위를 초과할 경우 증가율이 감소하였기에 24시간이 적절하다.In an embodiment of the present invention, the hot water extraction step is performed by hot water extraction at a temperature of 80-90 ° C for 24 hours. The hot water extraction time was increased up to 24 hours in the yield and beta glucan contents in proportion to the time increase rate.
본 발명의 일실시예에 있어서, 상기 에탄올 정제 단계는 열수 추출이 끝난 후 추출물과 동일한 용량의 에탄올을 2-3회 반복해 가한 후 여과하고, 다시 같은 양의 에탄올을 1-2회 가하여 정제하는 것을 특징으로 한다. In one embodiment of the present invention, the ethanol purification step may be performed after the hot water extraction is completed, The ethanol is repeated 2-3 times, filtered, and then the same amount of ethanol is added 1-2 times to purify.
본 발명의 일실시예에 있어서, 상기 에탄올 정제 단계는, 열수 추출이 끝난 추출물에 1배량의 에탄올을 가해 흔들어 섞은 후 4℃에서 4-8시간 방치하고, 다시 1배량의 에탄올을 가해 흔들어 섞고 4℃에서 24시간 방치한 후 여과한 후, 다시 1배량의 에탄올을 가해 흔들어 섞은 후 24시간 방치하는 방법으로 이루어질 수 있다. 본 발명의 일실시예에 있어서 상기 에탄올을 가하는 횟수는 2-4회가 적절하다.In one embodiment of the present invention, the ethanol-extracting step comprises: shaking mixing 1-fold volume of ethanol to the extracted hot-water-extracted extract, leaving it at 4 ° C for 4-8 hours, adding 1-fold volume of ethanol, Deg.] C for 24 hours, then filtered, and then one volume of ethanol is added thereto, followed by shaking, followed by allowing to stand for 24 hours. In one embodiment of the present invention, the number of times the ethanol is added is suitably 2-4 times.
본 발명의 일실시예에 있어서, 상기 추출방법은 상황버섯 분말과 pH 3.5-5.5의 물을 10-30%의 용매비로 혼합하고, 0.6-0.7 % (v/v)의 Viscozyme을 가해 40-60℃의 온도에서 6-8시간 교반하여 얻은 수득물을 pH 6-7로 조정하여 80-90℃에서 24시간 열수 추출한 후 2-4회에 걸쳐 에탄올을 가해 정제하는 단계를 포함할 수 있다.In one embodiment of the present invention, the extraction method comprises mixing the mushroom powder with water at a pH of 3.5-5.5 at a solvent ratio of 10-30%, adding Viscozyme of 0.6-0.7% (v / v) ° C. for 6-8 hours, adjusting the pH of the obtained product to pH 6-7, subjecting to hot water extraction at 80-90 ° C. for 24 hours, and then adding ethanol for 2-4 times for purification.
본 발명의 일실시예에 있어서, 상기 추출방법은 에탄올 정제가 끝난 다음, 농축 및 동결 건조하는 단계를 추가로 포함할 수 있다.In one embodiment of the present invention, the extraction method may further include a step of concentrating and lyophilizing after completion of the ethanol purification.
본 발명의 추출방법에 의해 추출된 베타글루칸 추출물은 기존의 추출법에 의해 추출된 것보다 높은 순도와 함량을 나타내며, 우수한 항암 활성을 가지는 것을 확인했다. 따라서 본 발명의 추출물은 항암 활성을 나타내는 약학적 조성물 또는 기능성 식품 조성물로 활용될 수 있다.The beta-glucan extract extracted by the extraction method of the present invention showed higher purity and content than that extracted by the conventional extraction method, and it was confirmed that it has excellent anticancer activity. Therefore, the extract of the present invention can be utilized as a pharmaceutical composition or a functional food composition exhibiting anticancer activity.
도 1은 본 발명의 일실시예에 따른 상황버섯으로부터 베타글루칸을 추출하는 공정을 기재한 것이다.
도 2는 본 발명의 추출방법으로 추출한 상황버섯 베타글루칸의 B16F10 cell에 대한 세포 독성을 측정한 결과이다.
도 3은 본 발명의 추출방법으로 추출한 상황버섯 베타글루칸의 SK-MEL-5 cell에 대한 세포 독성을 측정한 결과이다.
도 4는 본 발명의 추출방법으로 추출한 상황버섯 베타글루칸의 B16F10 cell에 대한 항암 활성을 측정한 결과이다.
도 5는 본 발명의 추출방법으로 추출한 상황버섯 베타글루칸의 SK-MEL-5 cell에 대한 항암 활성을 측정한 결과이다.FIG. 1 illustrates a process for extracting beta-glucan from a mushroom according to an embodiment of the present invention.
FIG. 2 shows the results of measurement of cytotoxicity against B16F10 cells of the mushroom beta-glucan extracted by the extraction method of the present invention.
FIG. 3 shows the results of measurement of cytotoxicity of SK-MEL-5 cell of the mushroom beta-glucan extracted by the extraction method of the present invention.
FIG. 4 shows the results of measuring anticancer activity against B16F10 cells of the mushroom beta-glucan extracted by the extraction method of the present invention.
FIG. 5 shows the result of measuring the antitumor activity of SK-MEL-5 cell of the mushroom beta-glucan extracted by the extraction method of the present invention.
이하에서는 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 다만, 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다 할 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. It should be understood, however, that these examples are for illustrative purposes only and are not to be construed as limiting the scope of the present invention.
<실시예 1> ≪ Example 1 >
상황버섯으로부터 베타글루칸의 추출Extraction of beta-glucan from mushroom
25 mesh 이상으로 분쇄한 상황버섯(Phellinus baumii) 분말에 10-30 배(중량비)의 용매비로 0.01N HCl로 pH 3.5-5.5의 물을 혼합하고, 0.6-0.7 % (v/v)의 Viscozyme을 가해 40-60℃의 온도에서 6-8시간 교반하여 얻은 수득물을, 0.01N의 NaOH를 이용하여 pH를 7로 조절한 다음, 80-90℃에서 24시간 열수 추출한 후 2-4회에 걸쳐 에탄올을 가해 정제하고, 이를 농축 및 동결 건조하여 베타글루칸 추출물을 얻었다. Phellinus baumii powder crushed at 25 mesh or more was mixed with water at a pH of 3.5-5.5 with 0.01N HCl at a solvent ratio of 10-30 times (weight ratio), and 0.6-0.7% (v / v) Viscozyme The resulting mixture was stirred at a temperature of 40-60 ° C for 6-8 hours and the resulting solution was adjusted to
위와 같이 에탄올 정제 횟수를 2-4회로 한정한 이유는 2-4회 정제할 경우 추출물 하단에 노란 빛을 띠는 정제물이 많이 생성되었기 때문이다. The reason for limiting the number of times of ethanol purification to 2-4 times as described above is that, when refining 2-4 times, a lot of purified water having yellowish light is produced at the bottom of the extract.
또한, 상기 열수 추출 단계의 추출 시간을 80-90℃의 온도에서 24시간으로 한정한 이유는 아래 표 1과 같이 24시간까지는 수율 및 베타글루칸 함량이 시간 증가율에 비례하여 증가하였으나, 이 범위를 초과할 경우 증가율이 감소하였기에 24시간이 최적의 추출 시간으로 판단되었기 때문이다.The reason why the extraction time of the hot water extraction step was limited to 24 hours at a temperature of 80-90 DEG C is that the yield and beta-glucan content increased in proportion to the time increase rate until 24 hours as shown in Table 1 below, , The growth rate was decreased, and the optimum extraction time was determined to be 24 hours.
[비교예 1][Comparative Example 1]
전체적으로 상기 실시예 1과 동일한 방법으로 수행하되, 효소를 처리하는 전처리 과정과 에탄올 정제 과정을 생략하고 열수 추출만 시행하였다.The pretreatment process for treating the enzyme and the ethanol refining process were omitted and only the hot water extraction was performed in the same manner as in Example 1 as a whole.
[비교예 2][Comparative Example 2]
전체적으로 상기 실시예 1과 동일한 방법으로 수행하되, 효소를 처리하는 전처리 과정을 생략하고, 열수 추출 후 약 2-4배량의 에탄올로 정제하였다.The pretreatment process for treating the enzyme was omitted, and the product was extracted with hot water and purified with about 2-4 times ethanol.
[비교예 3][Comparative Example 3]
전체적으로 상기 실시예 1과 동일한 방법으로 수행하되, 에탄올 정제 과정을 생략하고, 효소 전처리 후 열수 추출하였다. As a whole, the same procedure as in Example 1 was carried out, except that the ethanol purification process was omitted, followed by pretreatment with an enzyme and hot water extraction.
상기 실시예 1 및 비교예들에 의해 얻은 수득물의 베타글루칸 순도 및 함량은 하기 표 2와 같다. 베타글루칸의 순도 정량은 Mushroom and Yeast -glucan assay kit (Megazyme, Wicklow, Ireland)를 이용하여 측정한 총 글루칸(total glucan) 함량에서 알파글루칸(α-glucan) 함량을 제외한 값으로 계산하였다. 베타글루칸의 함량은 원물 100 g당 베타글루칸의 양(g)으로 나타내었다.The purity and content of beta-glucan in the obtained product obtained in Example 1 and Comparative Examples are shown in Table 2 below. The purity of β-glucan was calculated by subtracting the content of α-glucan from the total glucan content measured by Mushroom and Yeast-glucan assay kit (Megazyme, Wicklow, Ireland). The content of beta-glucan is expressed as the amount of beta-glucan per 100 g of the raw material (g).
상기 표 2에서 알 수 있는 바와 같이 효소 전처리 및/또는 에탄올 정제 과정을 생략한 경우에 비해 위 공정을 모두 거친 본 발명의 추출물의 베타글루칸 순도 및 함량이 월등히 높은 것을 알 수 있다. 구체적으로 본 발명의 정제 방법을 통하여 추출된 베타글루칸 추출물은 기존의 열수 추출법(비교예 1)에 의한 추출물에 비해 약 3.1배의 높은 순도와 약 3.4배의 높은 함량을 가지며, 종래의 열수 추출 후 정제하는 방법(비교예 2)에 의한 추출물에 비해 약 2.2배의 높은 순도와 약 13.2배의 높은 함량을 나타냈다.As can be seen from the above Table 2, the purity and content of beta-glucan of the extract of the present invention, which has undergone all of the above steps, is much higher than that of the case of omitting the enzyme pretreatment and / or ethanol purification process. Specifically, the beta-glucan extract extracted through the purification method of the present invention has about 3.1 times higher purity and about 3.4 times higher content than the extract obtained by the conventional hot water extraction method (Comparative Example 1) Compared with the extract obtained by the purification method (Comparative Example 2), the purity was about 2.2 times higher and the content was about 13.2 times higher.
<< 실시예Example 2> 2>
본 발명의 The 베타글루칸Beta Glucan 추출물의 세포독성 측정 Cytotoxicity measurement of extract
상기 실시예 1의 방법으로 얻은 베타글루칸 추출물의 세포 독성은 B16F10 cell과 SK-MEL-5 cell에 대한 MTT assay를 실시하여 대조구의 세포 생존율에 비교하여 나타내었다(도 2,3).The cytotoxicity of the beta-glucan extract obtained by the method of Example 1 was compared with the cell viability of the control by MTT assay for B16F10 cell and SK-MEL-5 cell (FIGS.
MTT assay의 실험 방법은 다음과 같다. B16F10 cell과 SK-MEL-5 cell을 96 well plate에 5.0 × 104 cell/mL로 분주한 후 부착 및 안정화를 위하여 37℃의 CO2 incubator에서 24시간 동안 배양하였다. 시료의 농도는 100 μg/mL로부터 희석하였고, 희석된 시료를 배양된 세포에 처리하여 다시 24시간 동안 배양하였다. 배양액을 제거한 후 10% MTT(Thiazolylblue tetrazolium bromide) solution (5 mg/mL in phosphate-bufferedsaline(PBS)) 100 μL를 가하여 다시 1시간 동안 배양하였다. 배양액을 제거하고, DMSO 100 μL를 가하여 생성된 formazan을 용해시킨 후 Victor3 1420 multiable counter(PerkinElmer Inc., Boston, MA, USA)를 이용하여 590 nm에서 흡광도를 측정하였다. 결과는 대조구와 비교하여 나타내었다.The experimental method of MTT assay is as follows. B16F10 cells and SK-MEL-5 cells were seeded at 5.0 × 10 4 cells / mL in a 96-well plate and cultured in a CO 2 incubator at 37 ° C for 24 hours for attachment and stabilization. The concentration of the sample was diluted from 100 μg / mL, and the diluted sample was treated with cultured cells and cultured for another 24 hours. After removing the culture medium, 100 μL of 10% MTT (Thiazolylblue tetrazolium bromide) solution (5 mg / mL in phosphate-buffered saline (PBS)) was added and incubated again for 1 hour. After removing the culture medium, 100 μL of DMSO was added and the resulting formazan was dissolved. The absorbance was measured at 590 nm using a Victor3 1420 multiable counter (PerkinElmer Inc., Boston, Mass., USA). The results were compared with the control.
그 결과, B16F10의 경우 대조구의 세포 생존율을 100%로 하였을 때 모든 실시예 및 비교예들에서 1~100 μg/mL의 농도에서 세포 생존율이 80% 이상으로 나타나 세포독성을 보이지 않은 반면(도 2), SK-MEL-5에 대해서는 비교예 3의 경우 100 μg/mL의 농도로 처리하였을 때 세포 생존율이 75%로 나타나 약간의 세포독성을 보였다(도 3).As a result, when the cell survival rate of the control was 100%, the cell survival rate was more than 80% at a concentration of 1 to 100 μg / mL in all the examples and comparative examples, ) And for SK-MEL-5, cell viability was 75% when treated with the concentration of 100 μg / mL for Comparative Example 3 (FIG. 3).
<< 실시예Example 3> 3>
본 발명의 The 베타글루칸Beta Glucan 추출물의 항암 활성 Anticancer activity of extract
본 발명의 방법으로 얻은 베타글루칸 추출물에 대한 세포 독성 실험 결과(상기 실시예 2 참조) 독성이 나타나지 않았던 농도 중 10 μg/mL의 추출물로 항암 활성을 측정한 결과, 종래의 기술에 비해 우수한 항암 활성을 가지는 것을 확인하였다. As a result of the cytotoxicity test on the beta-glucan extract obtained by the method of the present invention (see Example 2 above), the anticancer activity was measured with an extract of 10 μg / mL in the concentration where no toxicity was observed. As a result, .
항암 활성은 B16F10 cell과 SK-MEL-5 cell에 대한 in vitro wound healing assay를 실시하여 wound의 거리로 활성의 정도를 비교하였다(도 4,5). 양성 대조구(Positive control)로는 10 μg/mL의 Resveratrol을 사용하였다.Anticancer activity was measured by in vitro wound healing assay on B16F10 cells and SK-MEL-5 cells (Fig. 4 and 5). Resveratrol (10 μg / mL) was used as a positive control.
in vitro wound healing assay의 실험 방법은 다음과 같다. B16F10 cell과 SK-MEL-5 cell을 6 well plate에 3 × 105 cells/well로 분주한 후 37℃의 CO2 incubator에서 24시간 동안 배양하였다. 이후 yellow pipette tip을 이용하여 cell의 표면에 wound를 형성시키고 배양액을 교체하였다. 시료를 3, 10, 30 μg/mL의 농도로 처리하여 37℃의 CO2 incubator에서 배양하면서 0, 6, 12시간 간격으로 healing 정도를 현미경(ECLIPSE TE2000-U, Nikon, Japan)으로 관찰하였다. Wound healing 비율은 wound의 거리를 측정하여 억제활성의 정도를 대조구와 비교하였다(표 3).The experimental method of in vitro wound healing assay is as follows. B16F10 cells and SK-MEL-5 cells were seeded at 3 × 10 5 cells / well in a 6-well plate and cultured in a CO 2 incubator at 37 ° C for 24 hours. Then, a yellow pipette tip was used to form a wound on the surface of the cell and the culture medium was replaced. The samples were treated at 3, 10, and 30 μg / mL, and incubated at 37 ° C in a CO 2 incubator at 0, 6, and 12 hours intervals. The degree of healing was monitored with a microscope (ECLIPSE TE2000-U, Nikon, Japan). Wound healing rate was measured by measuring the distance of wound and the degree of inhibitory activity was compared with the control (Table 3).
그 결과, 도 4 및 5에 나타낸 바와 같이, 모든 처리구에서 대조구(control)에 비해 암세포 증식 억제 활성이 높게 나타났다. 특히, 실시예 1과 비교예 2의 경우 positive control보다도 항암 활성이 우수하였으며, B16F10 cell과 SK-MEL-5 cell 모두에서 실시예 1의 항암 활성이 가장 우수한 것을 확인하였다.As a result, as shown in Figs. 4 and 5, cancer cell proliferation inhibitory activity was higher in all treatments than control. In particular, the anticancer activity of Example 1 and Comparative Example 2 was superior to the positive control, and it was confirmed that the anticancer activity of Example 1 was the best in both of B16F10 cell and SK-MEL-5 cell.
controlPositive
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (5)
상기 혼합물에 비스코자임(viscozyme)을 처리하는 효소 처리 단계;
상기 효소 처리 단계를 거친 결과물의 pH를 6-7로 조정하는 단계;
상기 pH를 6-7로 조정한 결과물을 열수 추출하는 단계; 및
상기 열수 추출물을 에탄올로 2-4회 정제하는 단계를 포함하는, 상황버섯으로부터 베타글루칸을 추출하는 방법. Mixing 10 to 30 parts by weight of water having a pH of 3.5 to 5.5 in 1 part by weight of the ground mushroom powder;
An enzyme treatment step of treating the mixture with a viscozyme;
Adjusting the pH of the resulting product to 6-7;
Adjusting the pH to 6-7, and subjecting the resultant to hot water extraction; And
The method of extracting beta-glucan from a mushroom comprising the step of purifying the hot-water extract with ethanol 2-4 times.
상기 효소 처리 단계의 용매는 pH 4의 물인 것을 특징으로 하는 방법.The method according to claim 1,
Wherein the solvent of the enzyme treatment step is water having a pH of 4.
상기 효소 전처리 단계는 0.6-0.7% (v/v)의 비스코자임을 가한 후 40-60℃의 온도에서 6-8시간 동안 교반하는 것을 특징으로 하는 방법.The method according to claim 1,
Wherein the enzyme pretreatment step is performed by adding 0.6 to 0.7% (v / v) viscose and stirring at a temperature of 40 to 60 DEG C for 6-8 hours.
상기 열수 추출 단계는 80-90℃의 온도에서 24시간 동안 열수 추출 하는 것을 특징으로 하는 방법.The method according to claim 1,
Wherein the hot water extraction step is hydrothermal extraction at a temperature of 80-90 DEG C for 24 hours.
상기 에탄올 정제 단계는 열수 추출이 끝난 후 열수 추출물 중량의 1배 중량의 에탄올을 2-3회 반복해 가한 후 여과하고, 다시 같은 양의 에탄올을 1-2회 가하여 정제하는 것을 특징으로 하는 방법.The method according to claim 1,
Wherein the ethanol is purified by repeating ethanol twice or more times by weight of the weight of the hot water extract after the hot water extraction, and then filtering the same by adding the same amount of ethanol 1-2 times.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160128209A KR101879506B1 (en) | 2016-10-05 | 2016-10-05 | Extracting method of beta-glucan from Phellinus baumii |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160128209A KR101879506B1 (en) | 2016-10-05 | 2016-10-05 | Extracting method of beta-glucan from Phellinus baumii |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180037704A KR20180037704A (en) | 2018-04-13 |
KR101879506B1 true KR101879506B1 (en) | 2018-07-17 |
Family
ID=61974167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160128209A KR101879506B1 (en) | 2016-10-05 | 2016-10-05 | Extracting method of beta-glucan from Phellinus baumii |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101879506B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102540960B1 (en) * | 2023-01-27 | 2023-06-08 | 유광호 | Antibacterial composition comprising fig enzyme |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002262820A (en) * | 2001-03-07 | 2002-09-17 | Isao Horiuchi | Method for extracting active ingredient of mushrooms |
WO2004099428A1 (en) * | 2003-05-07 | 2004-11-18 | Kwan-Ho Kim | Extraction method of beta glucan from phellinus linteus through cell destruction and enzyme fermentation method |
KR20080111270A (en) * | 2007-06-18 | 2008-12-23 | 계명대학교 산학협력단 | Phellinus linteus extraxt, grain syrup and pepper paste comprising thereof |
KR20090121824A (en) * | 2008-05-23 | 2009-11-26 | 농업회사법인 하나바이오텍(주) | Producing process for water soluble beta-glucan |
KR20140094295A (en) * | 2013-01-22 | 2014-07-30 | 가톨릭대학교 산학협력단 | Pharmaceutical Composition Comprising High-Molecular Weight Polysaccharides Obtained from Phellinus linteus Fruit Body for Preventing or Treating Alzheimer's Disease |
KR20150103521A (en) * | 2014-03-03 | 2015-09-11 | (주)자연애제약 | Manufacturing method of composition having enhanced content beta glucan and anti oxidative activity by ultra high pressure or enzyme treatment of Grifola frondosa |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050100718A (en) | 2004-04-14 | 2005-10-20 | 박순영 | The beta-glucan obtained from fruit body of phellinus linteus and the pharmaceutical composition containing the same for anti-cancer |
KR20100119922A (en) | 2009-05-04 | 2010-11-12 | 한림대학교 산학협력단 | Anti-inflamatory composition containing betaglucan extracted from agrocybe chaxingu |
-
2016
- 2016-10-05 KR KR1020160128209A patent/KR101879506B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002262820A (en) * | 2001-03-07 | 2002-09-17 | Isao Horiuchi | Method for extracting active ingredient of mushrooms |
WO2004099428A1 (en) * | 2003-05-07 | 2004-11-18 | Kwan-Ho Kim | Extraction method of beta glucan from phellinus linteus through cell destruction and enzyme fermentation method |
KR20080111270A (en) * | 2007-06-18 | 2008-12-23 | 계명대학교 산학협력단 | Phellinus linteus extraxt, grain syrup and pepper paste comprising thereof |
KR20090121824A (en) * | 2008-05-23 | 2009-11-26 | 농업회사법인 하나바이오텍(주) | Producing process for water soluble beta-glucan |
KR20140094295A (en) * | 2013-01-22 | 2014-07-30 | 가톨릭대학교 산학협력단 | Pharmaceutical Composition Comprising High-Molecular Weight Polysaccharides Obtained from Phellinus linteus Fruit Body for Preventing or Treating Alzheimer's Disease |
KR20150103521A (en) * | 2014-03-03 | 2015-09-11 | (주)자연애제약 | Manufacturing method of composition having enhanced content beta glucan and anti oxidative activity by ultra high pressure or enzyme treatment of Grifola frondosa |
Also Published As
Publication number | Publication date |
---|---|
KR20180037704A (en) | 2018-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vishchuk et al. | Sulfated polysaccharides from brown seaweeds Saccharina japonica and Undaria pinnatifida: isolation, structural characteristics, and antitumor activity | |
Roca et al. | Production of yeast chitin–glucan complex from biodiesel industry byproduct | |
Gaitán-Hernández et al. | Review of bioactive molecules production, biomass, and basidiomata of shiitake culinary-medicinal mushrooms, Lentinus edodes (Agaricomycetes) | |
KR870001814B1 (en) | Process for preparing high molecular waight beta-1,3-glucan | |
JPH08259602A (en) | New polysaccharide substance | |
CN111690075B (en) | Water-soluble beta-glucan, preparation method thereof and application thereof in preparation of immune enhancement and anti-tumor medicines and health-care products | |
CN111978421B (en) | Phellinus igniarius polysaccharide and preparation and application thereof | |
CN107501429B (en) | Method for extracting bioactive β -glucan from sparassis crispa liquid fermentation mycelium | |
KR101124783B1 (en) | Medium composition for Phellinus linteus culture | |
Bisko et al. | Effects of cultivation parameters on intracellular polysaccharide production in submerged culture of the edible medicinal mushroom Lentinula edodes. | |
KR101879506B1 (en) | Extracting method of beta-glucan from Phellinus baumii | |
KR100695779B1 (en) | Microorganism producing fucoidan and method for producing fucoidan using the same | |
JP4183326B2 (en) | Hanabira bamboo extract | |
KR101804317B1 (en) | Aureobasidium pullulans YK1 produced by using UV and a producing method for β-glucan using the same | |
US20200317822A1 (en) | Method for Preparing Arabinogalacturonan from Tangerine Peel | |
CN102838689A (en) | Production process for extracting lentinan by fermentation method and product thereof | |
Zhao et al. | In vitro antioxidant and antitumor activities of polysaccharides extracted from the mycelia of liquid-cultured Flammulina velutipes | |
Zhuang et al. | Chemical modification and antitumor activity of polysaccharides from the mycelium of liquid-cultured Grifola frondosa | |
JPH0248161B2 (en) | ||
JPH01193265A (en) | Novel antitumor antibiotic sf2587 substance and its production | |
CN101117641B (en) | Method for preparing secoisolariciresinol diglucoside | |
KR20100070777A (en) | Mass producing method of grifola frondosa's mycelium-culture compound and immune active polysaccaharide | |
JPH1180206A (en) | Glucomannan separated from agaricus blazei mushroom culture and antitumor agent containing it as active ingredient | |
TW527421B (en) | Method for acquiring cell compositions by use cell apoptosis inducers | |
JPS6359679B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |